|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MAP3K2 |
Gene summary for MAP3K2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MAP3K2 | Gene ID | 10746 |
| Gene name | mitogen-activated protein kinase kinase kinase 2 | |
| Gene Alias | MEKK2 | |
| Cytomap | 2q14.3 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | A0A024RAH0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10746 | MAP3K2 | CA_HPV_1 | Human | Cervix | CC | 2.89e-03 | 7.99e-02 | 0.0264 |
| 10746 | MAP3K2 | CCI_2 | Human | Cervix | CC | 1.91e-04 | 5.86e-01 | 0.5249 |
| 10746 | MAP3K2 | CCI_3 | Human | Cervix | CC | 3.69e-03 | 4.89e-01 | 0.516 |
| 10746 | MAP3K2 | CCII_1 | Human | Cervix | CC | 2.50e-03 | -3.37e-01 | 0.3249 |
| 10746 | MAP3K2 | L1 | Human | Cervix | CC | 7.87e-06 | -2.84e-01 | 0.0802 |
| 10746 | MAP3K2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 7.38e-03 | -4.09e-01 | 0.0155 |
| 10746 | MAP3K2 | HTA11_347_2000001011 | Human | Colorectum | AD | 8.21e-04 | 3.02e-01 | -0.1954 |
| 10746 | MAP3K2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 4.56e-04 | -3.53e-01 | 0.0674 |
| 10746 | MAP3K2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 6.85e-08 | -3.43e-01 | 0.3005 |
| 10746 | MAP3K2 | A015-C-203 | Human | Colorectum | FAP | 2.04e-23 | -3.20e-01 | -0.1294 |
| 10746 | MAP3K2 | A015-C-204 | Human | Colorectum | FAP | 1.99e-03 | -3.14e-01 | -0.0228 |
| 10746 | MAP3K2 | A014-C-040 | Human | Colorectum | FAP | 9.46e-05 | -5.74e-01 | -0.1184 |
| 10746 | MAP3K2 | A002-C-201 | Human | Colorectum | FAP | 3.06e-13 | -4.01e-01 | 0.0324 |
| 10746 | MAP3K2 | A002-C-203 | Human | Colorectum | FAP | 3.73e-04 | -2.04e-01 | 0.2786 |
| 10746 | MAP3K2 | A001-C-119 | Human | Colorectum | FAP | 4.48e-07 | -4.30e-01 | -0.1557 |
| 10746 | MAP3K2 | A001-C-108 | Human | Colorectum | FAP | 1.06e-14 | -3.01e-01 | -0.0272 |
| 10746 | MAP3K2 | A002-C-205 | Human | Colorectum | FAP | 2.69e-18 | -4.57e-01 | -0.1236 |
| 10746 | MAP3K2 | A001-C-104 | Human | Colorectum | FAP | 2.64e-05 | -2.81e-01 | 0.0184 |
| 10746 | MAP3K2 | A015-C-005 | Human | Colorectum | FAP | 9.53e-03 | -2.96e-01 | -0.0336 |
| 10746 | MAP3K2 | A015-C-006 | Human | Colorectum | FAP | 1.37e-11 | -4.59e-01 | -0.0994 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00000751 | Liver | HCC | cell cycle checkpoint | 100/7958 | 169/18723 | 8.75e-06 | 1.02e-04 | 100 |
| GO:001021221 | Liver | HCC | response to ionizing radiation | 89/7958 | 148/18723 | 1.10e-05 | 1.26e-04 | 89 |
| GO:003109822 | Liver | HCC | stress-activated protein kinase signaling cascade | 138/7958 | 247/18723 | 1.43e-05 | 1.57e-04 | 138 |
| GO:005140322 | Liver | HCC | stress-activated MAPK cascade | 134/7958 | 239/18723 | 1.50e-05 | 1.64e-04 | 134 |
| GO:0045786 | Liver | HCC | negative regulation of cell cycle | 204/7958 | 385/18723 | 1.84e-05 | 1.99e-04 | 204 |
| GO:0045930 | Liver | HCC | negative regulation of mitotic cell cycle | 130/7958 | 235/18723 | 4.69e-05 | 4.50e-04 | 130 |
| GO:0007093 | Liver | HCC | mitotic cell cycle checkpoint | 77/7958 | 129/18723 | 6.00e-05 | 5.50e-04 | 77 |
| GO:007147921 | Liver | HCC | cellular response to ionizing radiation | 47/7958 | 72/18723 | 7.95e-05 | 7.07e-04 | 47 |
| GO:200102211 | Liver | HCC | positive regulation of response to DNA damage stimulus | 64/7958 | 105/18723 | 1.03e-04 | 8.88e-04 | 64 |
| GO:00714782 | Liver | HCC | cellular response to radiation | 104/7958 | 186/18723 | 1.48e-04 | 1.19e-03 | 104 |
| GO:00000771 | Liver | HCC | DNA damage checkpoint | 68/7958 | 115/18723 | 2.33e-04 | 1.77e-03 | 68 |
| GO:00467775 | Liver | HCC | protein autophosphorylation | 123/7958 | 227/18723 | 2.40e-04 | 1.80e-03 | 123 |
| GO:00103321 | Liver | HCC | response to gamma radiation | 37/7958 | 56/18723 | 3.13e-04 | 2.22e-03 | 37 |
| GO:00714802 | Liver | HCC | cellular response to gamma radiation | 23/7958 | 31/18723 | 3.47e-04 | 2.42e-03 | 23 |
| GO:0031570 | Liver | HCC | DNA integrity checkpoint | 71/7958 | 123/18723 | 4.64e-04 | 3.08e-03 | 71 |
| GO:1901988 | Liver | HCC | negative regulation of cell cycle phase transition | 132/7958 | 249/18723 | 4.97e-04 | 3.25e-03 | 132 |
| GO:00900683 | Liver | HCC | positive regulation of cell cycle process | 125/7958 | 236/18723 | 7.21e-04 | 4.40e-03 | 125 |
| GO:0010948 | Liver | HCC | negative regulation of cell cycle process | 152/7958 | 294/18723 | 8.50e-04 | 5.08e-03 | 152 |
| GO:1901976 | Liver | HCC | regulation of cell cycle checkpoint | 23/7958 | 33/18723 | 1.46e-03 | 7.75e-03 | 23 |
| GO:0044773 | Liver | HCC | mitotic DNA damage checkpoint | 48/7958 | 81/18723 | 1.72e-03 | 8.96e-03 | 48 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0491212 | Cervix | CC | GnRH signaling pathway | 26/1267 | 93/8465 | 8.72e-04 | 3.87e-03 | 2.29e-03 | 26 |
| hsa040109 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
| hsa04540 | Cervix | CC | Gap junction | 22/1267 | 88/8465 | 9.07e-03 | 2.85e-02 | 1.69e-02 | 22 |
| hsa0491213 | Cervix | CC | GnRH signaling pathway | 26/1267 | 93/8465 | 8.72e-04 | 3.87e-03 | 2.29e-03 | 26 |
| hsa0401012 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
| hsa045401 | Cervix | CC | Gap junction | 22/1267 | 88/8465 | 9.07e-03 | 2.85e-02 | 1.69e-02 | 22 |
| hsa04912 | Colorectum | AD | GnRH signaling pathway | 35/2092 | 93/8465 | 3.69e-03 | 1.90e-02 | 1.21e-02 | 35 |
| hsa049121 | Colorectum | AD | GnRH signaling pathway | 35/2092 | 93/8465 | 3.69e-03 | 1.90e-02 | 1.21e-02 | 35 |
| hsa049126 | Colorectum | FAP | GnRH signaling pathway | 28/1404 | 93/8465 | 8.16e-04 | 5.14e-03 | 3.13e-03 | 28 |
| hsa04010 | Colorectum | FAP | MAPK signaling pathway | 68/1404 | 302/8465 | 4.00e-03 | 1.67e-02 | 1.02e-02 | 68 |
| hsa049127 | Colorectum | FAP | GnRH signaling pathway | 28/1404 | 93/8465 | 8.16e-04 | 5.14e-03 | 3.13e-03 | 28 |
| hsa040101 | Colorectum | FAP | MAPK signaling pathway | 68/1404 | 302/8465 | 4.00e-03 | 1.67e-02 | 1.02e-02 | 68 |
| hsa049128 | Colorectum | CRC | GnRH signaling pathway | 25/1091 | 93/8465 | 2.11e-04 | 2.71e-03 | 1.84e-03 | 25 |
| hsa040102 | Colorectum | CRC | MAPK signaling pathway | 56/1091 | 302/8465 | 2.76e-03 | 1.77e-02 | 1.20e-02 | 56 |
| hsa049129 | Colorectum | CRC | GnRH signaling pathway | 25/1091 | 93/8465 | 2.11e-04 | 2.71e-03 | 1.84e-03 | 25 |
| hsa040103 | Colorectum | CRC | MAPK signaling pathway | 56/1091 | 302/8465 | 2.76e-03 | 1.77e-02 | 1.20e-02 | 56 |
| hsa040108 | Lung | IAC | MAPK signaling pathway | 62/1053 | 302/8465 | 3.54e-05 | 6.38e-04 | 4.24e-04 | 62 |
| hsa0491210 | Lung | IAC | GnRH signaling pathway | 20/1053 | 93/8465 | 9.36e-03 | 3.62e-02 | 2.41e-02 | 20 |
| hsa0401011 | Lung | IAC | MAPK signaling pathway | 62/1053 | 302/8465 | 3.54e-05 | 6.38e-04 | 4.24e-04 | 62 |
| hsa0491211 | Lung | IAC | GnRH signaling pathway | 20/1053 | 93/8465 | 9.36e-03 | 3.62e-02 | 2.41e-02 | 20 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MAP3K2 | SNV | Missense_Mutation | c.1550N>T | p.Gly517Val | p.G517V | Q9Y2U5 | protein_coding | deleterious(0) | possibly_damaging(0.566) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| MAP3K2 | SNV | Missense_Mutation | c.1210N>A | p.Glu404Lys | p.E404K | Q9Y2U5 | protein_coding | tolerated(0.1) | benign(0.348) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| MAP3K2 | SNV | Missense_Mutation | novel | c.928N>G | p.Thr310Ala | p.T310A | Q9Y2U5 | protein_coding | tolerated(0.41) | benign(0.003) | TCGA-HN-A2NL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| MAP3K2 | SNV | Missense_Mutation | novel | c.832A>G | p.Asn278Asp | p.N278D | Q9Y2U5 | protein_coding | tolerated(0.17) | benign(0.044) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MAP3K2 | SNV | Missense_Mutation | novel | c.883N>G | p.Leu295Val | p.L295V | Q9Y2U5 | protein_coding | deleterious(0.02) | benign(0) | TCGA-VS-A8EL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MAP3K2 | SNV | Missense_Mutation | c.987N>T | p.Arg329Ser | p.R329S | Q9Y2U5 | protein_coding | tolerated(0.18) | benign(0.071) | TCGA-AA-3494-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folinic | PR | |
| MAP3K2 | SNV | Missense_Mutation | novel | c.740T>G | p.Phe247Cys | p.F247C | Q9Y2U5 | protein_coding | tolerated(0.26) | benign(0.005) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MAP3K2 | SNV | Missense_Mutation | c.1601G>A | p.Ser534Asn | p.S534N | Q9Y2U5 | protein_coding | tolerated(0.56) | benign(0.066) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
| MAP3K2 | SNV | Missense_Mutation | rs376189453 | c.1018G>A | p.Val340Ile | p.V340I | Q9Y2U5 | protein_coding | tolerated(0.05) | benign(0.158) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD |
| MAP3K2 | SNV | Missense_Mutation | novel | c.219N>C | p.Lys73Asn | p.K73N | Q9Y2U5 | protein_coding | deleterious(0.03) | possibly_damaging(0.735) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 10746 | MAP3K2 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | CI-1040 | CI-1040 | ||
| 10746 | MAP3K2 | SERINE THREONINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME | inhibitor | 249565786 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |